Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of Bemnifosbuvir and Ruzasvir in healthy volunteers
NCT05731843Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir and ruzasvir in hepatitis C (HCV) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Pharmacokinetics (PK) of Bemnifosbuvir at Day 18 and Pharmacokinetics (PK) of Ruzasvir at Day 18. Started Jan 2023; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05731843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731843.